97 reports

  • 6.6 OTHER BRANDED DIRECT-ACTING ANTIVIRALS
  • 7.2 REDUCING THE OVERALL COST BURDEN OF DIRECT-ACTING ANTIVIRAL TREATMENT

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), Hepatocellular...

  • Antiviral
  • Market Size
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • 8.2.1 ANTIVIRALS
  • presents clinical trial designs for CMV pipeline antivirals.

Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027 Summary For nearly two decades, the Cytomegalovirus (CMV) therapeutics landscape has been dominated by ganciclovir and valganciclovir, with modest growth in the form of additional antivirals targeting DNA replication. The 2017 approval...

  • Antiviral
  • Japan
  • United States
  • Atara Biotherapeutics, Inc.
  • Moderna Therapeutics, Inc.

The two major HIV subtypes are HIV-## and HIV-##.

  • Antiviral
  • HIV AIDS
  • Therapy
  • World
  • Market Shares
  • Global Hepatitis B Treatment - Drug Pipeline
  • Global Hepatitis B Treatment - Drug Pipeline

Top ## players hold majority of stake in the market ##.

  • Antiviral
  • World
  • Market Size
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

This influence varies from one industry to another, but also from one period of time to another.

  • Antiviral
  • Therapy
  • World
  • Demand
  • 6.3 GILEAD

HIV (Human immunodeficiency virus) is a retrovirus which causes HIV infection and attacks the CD-4 cells (T-cells) in the immune system of human body. HIV reduces the number of T-cells in the body and makes the immune system vulnerable to life-threatening infections and cancers. An infected person cannot get rid of this virus...

  • Antiviral
  • World
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

Segments Covered ##) Global Antiviral Drugs Market a.

  • Antiviral
  • APAC
  • United States
  • World
  • Demand

Hepatitis C Therapies Market 2017-2027 ##.

  • Antiviral
  • Hepatitis Treatment
  • Forecast
  • Market Shares
  • Market Size
  • MARKET SIZE AND FORECAST
  • ANTIVIRAL DRUGS MARKET IN EMEA

About Antiviral Drugs Antiviral drugs are agents used to cure a viral infection by inhibiting the growth of viral pathogens. There are two types of antiviral agents which includes narrow-spectrum antiviral agents and broad-spectrum antiviral agents. Technavio’s analysts forecast the global antiviral drugs market to grow...

  • Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.
  • ANTIVIRAL EFFICACY OF HEPSERA IN HBEAG-POSITIVE PATIENTS
  • ANTIVIRAL EFFICACY OF BARACLUDE COMPARED WITH EPIVIR-HBV

Hepatitis B Virus (HBV) Therapeutics - US Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains...

  • Antiviral
  • United States
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • ANTIVIRAL EFFICACY OF HEPSERA IN HBEAG-POSITIVE PATIENTS
  • ANTIVIRAL EFFICACY OF BARACLUDE IN EPIVIR-HBV-REFRACTORY PATIENTS

Hepatitis B Virus (HBV) Therapeutics - China Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains...

  • Antiviral
  • China
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • ANTIVIRAL EFFICACY OF HEPSERA IN HBEAG-POSITIVE PATIENTS
  • ANTIVIRAL EFFICACY OF BARACLUDE COMPARED WITH EPIVIR-HBV

Hepatitis B Virus (HBV) Therapeutics - Japan Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains...

  • Antiviral
  • Japan
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • TREATMENT ACCESS
  • 6.6 CHINA

ANTIVIRAL ACTIVITY OF APRICITABINE IN TREATMENT-EXPERIENCED HIV-##-INFECTED PATIENTS WITH M##V WHO ARE FAILING COMBINATION THERAPY.

  • Antiviral
  • East Asia
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare Ltd.

According to the WHO, cases of viral infections increase by more than ## million each year with around ## million patients already suffering from one of the four Sexually Transmitted Infections (STIs), such as Acquired Immunodeficiency Syndrome (AIDS).

  • Antiviral
  • Therapy
  • United States
  • Forecast

Interferon and Antiviral ##. ##. ##. ##.

  • Antiviral
  • Hepatitis Treatment
  • Therapy
  • World
  • Market Size
  • SHARE OF INFECTIOUS DISEASES MARKET IN PHARMACEUTICAL MARKET IN CHINA 2015
  • HIGHLIGHTS

It blocks IL-## receptor signaling and prevents the binding of IL-##alpha and IL-## beta to the IL-## receptor.

  • Antiviral
  • China
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • BUSINESS SEGMENTATION BY REVENUE
  • GILEAD SCIENCES

It has also signed a contract worth $## billion with Modern Pharmaceuticals for its messenger RNA therapeutics platform for developing new antiviral vaccines and passive immunity therapies.

  • Antiviral
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

(USA) ##.

  • Anti-Infective
  • Antiviral
  • Hepatitis
  • World
  • Market Shares
  • Brazil: Fastest Growing Therapy Classes (ATC 3)

New drugs are classified into one of the categories described in Table ##, below.

  • Antiviral
  • Pharmaceutical
  • Brazil
  • Demand
  • GlaxoSmithKline plc
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

ANTIVIRAL THERAPY SUPPRESSES THE REPLICATION OF HIV INFECTION IN THE BODY.

  • Antiviral
  • China
  • Demand
  • Market Size
  • Supply

Hepatitis C

4546 5000 3864
  • DIRECT-ACTING ANTIVIRALS TARGET KEY VIRAL NON-STRUCTURAL PROTEINS NECESSARY FOR HCV REPLICATION
  • Pivotal studies supporting approvals of Zepatier

The $21bn hepatitis C market is expected to undergo a net decline from 2016 as new entrants intensify pricing competition and patient numbers are exhausted from the early 2020s. This report addresses the following questions: - To what extent will the launch of Merck & Co’s Zepatier at a discounted price affect sales of...

  • Antiviral
  • European Union
  • Japan
  • North America
  • United States

The company has also signed a deal worth $## billion with Moderna for its messenger RNA therapeutics platform in developing new antiviral vaccines and passive immunity therapies.

  • Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson

(USA) ##.

  • Antiviral
  • Hepatitis
  • United States
  • World
  • Market Shares
  • ANTIVIRAL EFFICACY OF BARACLUDE IN EPIVIR-HBV-REFRACTORY PATIENTS
  • ANTIVIRAL EFFICACY OF HEPSERA IN HBEAG-POSITIVE PATIENTS

Hepatitis B Virus (HBV) Therapeutics - 5EU Drug Forecast and Market Analysis to 2024 Summary Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains...

  • Antiviral
  • World
  • Forecast
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • KEY FINDINGS

CHINA AND THE US ARE LEADING IN COUNTRY-SPECIFIC DRUG DEVELOPMENT. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Pre-registration ## ## Filing rejected/ Withdrawn Phase III ## ## ## ## Phase II ## ## ## Phase I ## ## ## ## Phase ## IND/ CTA Filed

  • Antiviral
  • China
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • HIV TREATMENT DRUGS INDUSTRY ASSESSMENTS

Antiviral therapy suppresses the replication of HIV infection in the body.

  • Antiviral
  • China
  • Co. Shanghai Boeringer Ingelheim Pharmaceutical Co., Ltd.
  • Ltd. Beijing Sanjiu Wandong Pharmaceutical Co., Ltd.
  • UNAIDS
  • COMMERCIAL ASSESSMENT - CURRENT & FUTURE PLAYERS

COMMERCIAL ASSESSMENT - CURRENT & FUTURE PLAYERS BRISTOL-MYERS SQUIBB SOLD ITS ANTIVIRAL R& D BUSINESS, INCLUDING HIV PIPELINE ASSETS, TO VIIV HEALTHCARE IN DECEMBER 2015.

  • Antiviral
  • United States
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • ViiV Healthcare Ltd.
  • 3.4.2 ANTIVIRAL THERAPY
  • RECOMMENDED ANTIVIRAL REGIMENS FOR THE MANAGEMENT OF GH IN IMMUNOCOMPETENT PATIENTS

Opportunity Analyzer: Genital Herpes - Opportunity Analysis and Forecasts to 2023 Summary Genital herpes (GH) is a life-long viral infection of the genitalia and urogenital tract. It is one of the most common sexually transmitted infections (STIs) and is a leading cause of genital ulcers around the world. Patients...

  • Antiviral
  • Therapy
  • United States
  • Forecast
  • Genocea Biosciences, Inc.
  • 6.3.1 Phase II
  • 3. Hepatitis C - Approved Drugs Sales & Forecast

This study will evaluate the safety, tolerability and antiviral efficacy of Sofosbuvir with Ribavirin (RBV) participants with genotype ## or ## Hepatitis C virus (HCV) infection who have chronic renal insufficiency.

  • Antiviral
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Human Immunodeficiency Virus (HIV) - China Drug Forecast and Market Analysis to 2023 ## Table of Contents ## Table of Contents ## ## Introduction ## ##. ## Catalyst ## ##. ## Related Reports ## ##. ## Upcoming Related Reports ## ## Disease Overview ## ##. ## Etiology ## ##. ##. ## Viral Lifecycle ## ##. ##

  • Antiviral
  • Therapy
  • China
  • Demand
  • Forecast